Technical Analysis for ANNX - Annexon, Inc.

Grade Last Price % Change Price Change
grade D 24.44 -0.61% -0.15
ANNX closed down 0.61 percent on Friday, October 23, 2020, on 52 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical ANNX trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish -0.61%
Older End-of-Day Gignals for ANNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Immune System Antibody Autoimmunity Monoclonal Antibody Platform Technology Complement System

Is ANNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 31.84
52 Week Low 15.33
Average Volume 223,690
200-Day Moving Average 0.00
50-Day Moving Average 25.69
20-Day Moving Average 27.80
10-Day Moving Average 27.98
Average True Range 2.30
ADX 37.17
+DI 21.01
-DI 21.16
Chandelier Exit (Long, 3 ATRs ) 24.94
Chandelier Exit (Short, 3 ATRs ) 28.69
Upper Bollinger Band 31.32
Lower Bollinger Band 24.27
Percent B (%b) 0.02
BandWidth 25.35
MACD Line 0.39
MACD Signal Line 0.98
MACD Histogram -0.5948
Fundamentals Value
Market Cap 932.34 Million
Num Shares 38.1 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -109.01
Price-to-Sales 0.00
Price-to-Book 29.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.87
Resistance 3 (R3) 25.84 25.35 25.63
Resistance 2 (R2) 25.35 24.98 25.36 25.55
Resistance 1 (R1) 24.89 24.76 24.92 24.92 25.47
Pivot Point 24.40 24.40 24.41 24.41 24.40
Support 1 (S1) 23.94 24.03 23.97 23.97 23.41
Support 2 (S2) 23.45 23.81 23.46 23.33
Support 3 (S3) 22.99 23.45 23.25
Support 4 (S4) 23.02